Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.

Madsen NJ, Holmes CE, Serrano FA, Sobel BE, Schneider DJ.

Am J Cardiol. 2007 Aug 15;100(4):722-7. Epub 2007 Jun 26.

PMID:
17697836
3.
4.

A new role for FcgammaRIIA in the potentiation of human platelet activation induced by weak stimulation.

Canobbio I, Stefanini L, Guidetti GF, Balduini C, Torti M.

Cell Signal. 2006 Jun;18(6):861-70. Epub 2005 Oct 5.

PMID:
16169188
6.

Effects on platelet function of a direct acting antagonist of coagulation factor Xa.

Ringwala SM, Dibattiste PM, Schneider DJ.

J Thromb Thrombolysis. 2012 Oct;34(3):291-6.

PMID:
22528328
8.

Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa.

Gardiner EE, Karunakaran D, Arthur JF, Mu FT, Powell MS, Baker RI, Hogarth PM, Kahn ML, Andrews RK, Berndt MC.

Blood. 2008 Jan 1;111(1):165-74. Epub 2007 Sep 11.

10.

Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane.

Sullam PM, Hyun WC, Szöllösi J, Dong Jf, Foss WM, López JA.

J Biol Chem. 1998 Feb 27;273(9):5331-6.

11.

TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcγRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice.

Zhou Y, Abraham S, Renna S, Edelstein LC, Dangelmaier CA, Tsygankov AY, Kunapuli SP, Bray PF, McKenzie SE.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2315-2323. Epub 2016 Oct 20.

PMID:
27765766
12.

Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.

Schneider DJ, Sobel BE.

Coron Artery Dis. 2009 Mar;20(2):175-8. doi: 10.1097/MCA.0b013e32831edcd1.

PMID:
19194284
13.

The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine.

Farrell TP, Hayes KB, Sobel BE, Schneider DJ.

Am J Cardiol. 1999 Mar 1;83(5):770-4.

PMID:
10080435
14.

Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation.

Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray PF.

J Thromb Haemost. 2003 Feb;1(2):355-62.

15.

Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.

Aggarwal A, Whitaker DA, Rimmer JM, Solomon RJ, Gennari FJ, Sobel BE, Schneider DJ.

Nephrol Dial Transplant. 2004 Jun;19(6):1559-63. Epub 2004 Mar 19.

PMID:
15034156
16.

Drospirenone enhances GPIb-IX-V-mediated platelet activation.

Fan X, Chen X, Wang C, Dai J, Lu Y, Wang K, Liu J, Zhang J, Wu X.

J Thromb Haemost. 2015 Oct;13(10):1918-24. doi: 10.1111/jth.13109. Epub 2015 Sep 14.

PMID:
26264726
17.

Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.

Schneider DJ, Sobel BE.

J Thromb Thrombolysis. 2009 Jul;28(1):6-9. doi: 10.1007/s11239-008-0250-x. Epub 2008 Jul 8.

PMID:
18607689
18.

[Influence of hemodialysis on expression of glycoprotein lb platelets reactivity in patients with the end stage renal failure].

Brzósko S, Hryszko T, Zak J, Wysocka J, Małyszko J, Myśliwiec M.

Przegl Lek. 2002;59(10):823-5. Polish.

PMID:
12632921
19.
20.

Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.

Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S.

Atherosclerosis. 2014 Jan;232(1):119-24. doi: 10.1016/j.atherosclerosis.2013.10.027. Epub 2013 Nov 10.

PMID:
24401225

Supplemental Content

Support Center